chronic obstructive pulmonary disease
NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears
July 10, 2018Manufacturing and Production, Medical Communications, Research and Development COPD, NICE, antimicrobial resistance, chronic obstructive pulmonary disease, pharma
NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when …
NICE turns down AZ’s chronic obstructive pulmonary disease drug
February 13, 2017Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …
GSK 18 months ahead of the game with three-drug inhaler
November 21, 2016Medical Communications, Sales and Marketing GSK, Innoviva, chronic obstructive pulmonary disease
GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary …
GSK announce positive results for chronic obstructive pulmonary disease treatment
September 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing GlaxoSmithKline, Innoviva, Revlar Ellipta, chronic obstructive pulmonary disease
GlaxoSmithKline and its partner Innoviva have announced that its Relvar Ellipta achieved positive results in its COPD Salford lung study …
Europe must prepare for COPD ‘timebomb’
November 19, 2014Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease
Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
Pfizer and Boehringer pilot COPD campaign
November 9, 2010Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema
Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …
Almirall and Forest’s phase III COPD drug misses goal
November 3, 2010Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
Latest content
Five Facts about cardiovascular disease
